The 10th Chinese H. pylori and Digestive Diseases Forum was held in Beijing on August 21-23, 2015. Established in 2006, the forum has become one of the most important platforms for scientists, gastroenterologists and clinicians in relevant areas to exchange ideas and research results on H. pylori diagnosis and treatment in China. About 800 scientists and clinicians, including 130 nationally and internationally recognized experts in digestive disease area, participated in the meeting. Professor Barry Marshall, Nobel Prize laureate in Physiology or Medicine for his discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease, participated the meeting and give a lecture. Dr. Zhenkun Ma, founder and CEO of TenNor Therapeutics was invited to give a lecture on the development of a new generation of antibiotics for H. pylori eradication.

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com